Mark Schoenberg Sells 859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) Stock

UroGen Pharma Ltd. (NASDAQ:URGN) insider Mark Schoenberg sold 859 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $13.08, for a total value of $11,235.72. Following the completion of the transaction, the insider now directly owns 145,091 shares of the company’s stock, valued at $1,897,790.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

UroGen Pharma Stock Performance

URGN opened at $13.12 on Friday. The firm’s 50-day moving average price is $15.15 and its 200-day moving average price is $14.96. The company has a market cap of $307.66 million, a P/E ratio of -3.86 and a beta of 1.11. The company has a quick ratio of 7.93, a current ratio of 8.15 and a debt-to-equity ratio of 3.23. UroGen Pharma Ltd. has a 52-week low of $10.60 and a 52-week high of $20.70.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. As a group, equities analysts anticipate that UroGen Pharma Ltd. will post -3.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Coastal Bridge Advisors LLC boosted its holdings in UroGen Pharma by 4.1% in the second quarter. Coastal Bridge Advisors LLC now owns 38,500 shares of the company’s stock valued at $646,000 after purchasing an additional 1,500 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after buying an additional 1,119,019 shares during the period. Point72 Asset Management L.P. boosted its stake in shares of UroGen Pharma by 120.3% in the second quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after buying an additional 1,337,257 shares during the last quarter. Cubist Systematic Strategies LLC grew its holdings in UroGen Pharma by 630.9% during the second quarter. Cubist Systematic Strategies LLC now owns 44,949 shares of the company’s stock worth $754,000 after acquiring an additional 38,799 shares during the period. Finally, Great Point Partners LLC raised its position in UroGen Pharma by 10.9% during the second quarter. Great Point Partners LLC now owns 2,906,259 shares of the company’s stock valued at $48,767,000 after acquiring an additional 285,714 shares in the last quarter. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Guggenheim assumed coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Wednesday, August 14th. Oppenheimer lifted their price target on shares of UroGen Pharma from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. Finally, LADENBURG THALM/SH SH increased their price objective on UroGen Pharma from $48.00 to $53.50 and gave the company a “buy” rating in a report on Friday, June 14th.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.